ArticleVirchows Archiv : an international journal of pathology2026
Primary renal synovial sarcoma: a clinicopathological study of 23 cases highlighting the diagnostic value of SS18-SSX, TLE1, and INI1 immunohistochemistry panel.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Primary renal synovial sarcoma (PRSS) is an extremely rare neoplasm that presents considerable diagnostic challenges due to its morphological overlap with other renal tumors. In this multicenter study, 23 PRSS cases with confirmed SS18::SSX rearrangements and 112 non-PRSS renal tumors were included. Clinicopathological features and immunohistochemical expression were evaluated. Diagnostic performance of individual markers and their combinations was assessed using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy, and a practical diagnostic approach for PRSS was proposed. The cohort (n = 23) had a median age of 42.3 years with slight male predominance (56.5%). Most presented with loin pain, and the mean tumor size was 8.7 cm. After a mean follow-up of 25 months, 41.2% (7/17) died of disease. Histologically, 87% (20/23) of cases showed intersecting monophasic spindle-cell morphology with oval‑to‑spindle hyperchromatic nuclei, while 13% (3/23) were biphasic. Key immunohistochemical findings included positivity for SS18-SSX (56.5%), TLE1 (82.4%), BCL2 (75%), and EMA (25%), with reduced/mosaic INI1 expression in 73.9% of cases. SS18-SSX, TLE1, and INI1 formed the optimal diagnostic panel. The criterion of at least two positive or aberrant markers achieved the highest performance: accuracy 94.8%, sensitivity 69.6%, specificity 100%, PPV 100% and NPV 94.1%. Based on these findings, a practical diagnostic approach integrating morphology with SS18-SSX, TLE1, and INI1 immunohistochemistry was proposed. PRSS is a rare malignant tumor with a poor prognosis that presents significant diagnostic challenges. Our immunohistochemical panel (SS18-SSX, TLE1, INI1) enhances diagnostic accuracy and may assist in the triage of cases requiring molecular confirmation.
Indexed as
Identifiers
42371005What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.